Modality
Fusion Protein
MOA
C5i
Target
FGFR
Pathway
Autophagy
RACRCPSP
Development Pipeline
Preclinical
~May 2014
→ ~Aug 2015
Phase 1
~Nov 2015
→ ~Feb 2017
Phase 2
May 2017
→ Nov 2031
Phase 2Current
NCT04882015
2,013 pts·PSP
2017-05→2031-11·Recruiting
2,013 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-025.6y awayPh3 Readout· PSP
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Recruit…
Catalysts
Ph3 Readout
2031-11-02 · 5.6y away
PSP
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04882015 | Phase 2/3 | PSP | Recruiting | 2013 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| Tixatapinarof | Recursion | Approved | FGFR | |
| EXA-4696 | Exscientia | Phase 2/3 | KRASG12C | |
| ABS-5770 | Absci | Preclinical | FGFR |